Company Overview and News
June 20 (Reuters) - The following are the top stories on the business pages of British newspapers. Reuters has not verified these stories and does not vouch for their accuracy.
FOX BT.A LLOY JSAIY BTGOF LYG BT LLPH LLPK LLPJ LLPE JSNSF LLOBF LLPD LLPG LLDTF LLD5 LLD7 LLPC LLD6 LLD1 FOXA LLD2
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
BT.A SVTRF BTGOF STRNY TLTZY SVT BT TLTZF
MILAN, June 8 — European shares fell today as worries over global trade and an economic slowdown in the region weighed ahead of a European Central Bank meeting next week that could signal plans to wind down a massive monetary stimulus.
BT.A BTGOF BT
U.K.’s blue-chip stocks slumped Friday in a broader selloff across European equities, with investors preparing for what’s likely to be a tense gathering of leaders in the Group of Seven advanced economies in Quebec.
BT.A HRGLY LLOY BTGOF LYG BT HL LLPH LLPK LLPJ LLPE LLPD LLOBF LLPG HRGLF LLDTF LLD5 LLD7 LLPC LLD6 LLD1 LLD2
June 8 (Reuters) - Britain’s FTSE 100 index is seen opening 24 points lower at 7,680 on Friday, according to financial bookmakers, with futures up 0.67 percent ahead of the cash market open.
BP ENB LLOBF EBBNF BT.A ENBBF LLOY BTGOF LYG BP.A BP.B BT ENB LLPH LLPK BP LLPJ LLPE LLPD LLPG LLDTF LLD5 LLD7 LLPC BPAQF LLD6 LLD1 LLD2
Amazon.com Inc. (AMZN) secured rights to broadcast live Premier League soccer matches in the U.K. for the first time starting from the 2019-2020 season, as BT Group PLC (BT.A.LN) secured rights to a further 20 matches a season.
BT.A VOD VOD GLNG BTGOF CKHUY GBT BT BOLD CBB VODPF CKHUF WIFI MDCA CBB.PRB AQMS MAA
2018-06-18 - Asif
Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...
2018-06-11 - Asif
Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...
2018-06-11 - Asif
Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...
as of ET